MARIA CHIARAMONTE, M.D.; ANNAROSA FLOREANI, M.D.; DIEGO MARTINES, M.D.; FRANCA DE LAZZARI, M.D.; REMO NACCARATO, M.D.
To the editor: We read with interest the paper of Hoofnagle and associates (1) on clearance of hepatitis B surface antigen (HBsAg) after reactivation of hepatitis B virus (HBV) chronic infection during cancer chemotherapy. The authors suggest that drugs inducing such a phenomenon be considered in the treatment of chronic HBV infection.
Between 1969 and 1973 we conducted a therapeutic trial of chronic active hepatitis with intermittent courses of cyclophosphamide, 100 to 200 mg/d up to 4 to 5 g, repeated at 1 to 3 month intervals. In about half of the cases clinical improvement was seen (2, 3). A
Learn more about subscription options.
Register Now for a free account.
CHIARAMONTE M, FLOREANI A, MARTINES D, DE LAZZARI F, NACCARATO R. Hepatitis B Virus Infection and Cyclophosphamide. Ann Intern Med. 1982;97:451–452. doi: 10.7326/0003-4819-97-3-451_2
Download citation file:
Published: Ann Intern Med. 1982;97(3):451-452.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only